Chronic treatment with cisplatin induces replication-dependent sister chromatid recombination to confer cisplatin-resistant phenotype in nasopharyngeal carcinoma

Oncotarget

Volumn 5, Issue 15, 2014, Pages 6323-6337

  Su, Wen Pin ^a,b   Hsu, Sen Huei ^c   Wu, Cheng Kuei ^c   Chang, Song Bin ^c   Lin, Yi Ju ^c   Yang, Wen Bin ^c   Hung, Jan Jong ^c   Chiu, Wen Tai ^c   Tzeng, Shun Fen ^c   Tseng, Yau Lin ^a   Chang, Jang Yang ^a,d   Su, Wu Chou ^a   Liaw, Hungjiun ^c  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Cisplatin; Cisplatin resistant phenotype; Fanconi anemia; Homologous recombination; Nasopharyngeal carcinoma; Template switching

Indexed keywords

CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; FANCONI ANEMIA GROUP D2 PROTEIN; GAMMA HISTONE H2AX; HISTONE H2AX; PACLITAXEL; PROTEIN P53; UBIQUITIN CONJUGATING ENZYME 13; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; BIOACCUMULATION; CARCINOMA CELL LINE; CELL CYCLE PROGRESSION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE; DRUG SENSITIZATION; ENZYME PHOSPHORYLATION; FA GENE; FANCD2 GENE; FANCONI ANEMIA PATHWAY; GENE EXPRESSION; HOMOLOGOUS RECOMBINATION; HONE1 CELL; HONE6 CELL; LOW DRUG DOSE; MOLECULAR DYNAMICS; NASOPHARYNX CARCINOMA; PHENOTYPE; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; SISTER CHROMATID EXCHANGE; SURVIVAL RATE; TEMPLATE SWITCHING PATHWAY; TREATMENT DURATION; TUMOR SUPPRESSOR GENE; UBC13 GENE; DRUG EFFECTS; GENETIC RECOMBINATION; GENETICS; HUMAN; METABOLISM; NASOPHARYNGEAL NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; HUMANS; NASOPHARYNGEAL NEOPLASMS; PHENOTYPE; RECOMBINATION, GENETIC; SISTER CHROMATID EXCHANGE;

EID: 84906330203     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2210     Document Type: Article

References (59)

1. Muhammad N and Guo Z. Metal-based anticancer chemotherapeutic agents. Current opinion in chemical biology. 2014; 19C:144-153.
2. Gottesman MM. Mechanisms of cancer drug resistance. Annual review of medicine. 2002; 53:615-627.
3. Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, Crowley D, Bronson RT, Whittaker CA, Bhutkar A, Lippard SJ, Golub T, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 2010; 24(8):837-852.
4. Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC and Hemann MT. Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci U S A. 2010; 107(48):20786-20791.
5. Palagyi A, Neveling K, Plinninger U, Ziesch A, Targosz BS, Denk GU, Ochs S, Rizzani A, Meier D, Thasler WE, Hanenberg H, De Toni EN, Bassermann F, Schafer C, Goke B, Schindler D, et al. Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. Mol Cancer. 2010; 9:127.
6. Wang QE, Milum K, Han C, Huang YW, Wani G, Thomale J and Wani AA. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells. Mol Cancer. 2011; 10:24.
7. Branzei D and Foiani M. The DNA damage response during DNA replication. Curr Opin Cell Biol. 2005; 17(6):568- 575.
8. Branzei D and Foiani M. Maintaining genome stability at the replication fork. Nat Rev Mol Cell Biol. 2010; 11(3):208-219.
9. D'Andrea AD. BRCA1: a missing link in the Fanconi anemia/BRCA pathway. Cancer discovery. 2013; 3(4):376- 378.
10. Kee Y and D'Andrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 2010; 24(16):1680-1694.
11. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet. 2007; 8(10):735-748.
12. Huang M and D'Andrea AD. A new nuclease member of the FAN club. Nat Struct Mol Biol. 2010; 17(8):926-928.
13. Ciccia A, McDonald N and West SC. Structural and functional relationships of the XPF/MUS81 family of proteins. Annu Rev Biochem. 2008; 77:259-287.
14. Fekairi S, Scaglione S, Chahwan C, Taylor ER, Tissier A, Coulon S, Dong MQ, Ruse C, Yates JR, III, Russell P, Fuchs RP, McGowan CH and Gaillard PH. Human SLX4 is a Holliday junction resolvase subunit that binds multiple DNA repair/recombination endonucleases. Cell. 2009; 138(1):78-89.
15. Svendsen JM, Smogorzewska A, Sowa ME, O'Connell BC, Gygi SP, Elledge SJ and Harper JW. Mammalian BTBD12/ SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell. 2009; 138(1):63-77.
16. Hodskinson MR, Silhan J, Crossan GP, Garaycoechea JI, Mukherjee S, Johnson CM, Scharer OD and Patel KJ. Mouse SLX4 Is a Tumor Suppressor that Stimulates the Activity of the Nuclease XPF-ERCC1 in DNA Crosslink Repair. Mol Cell. 2014.
17. Petermann E and Helleday T. Pathways of mammalian replication fork restart. Nat Rev Mol Cell Biol. 2010; 11(10):683-687.
18. Kim H and D'Andrea AD. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 2012; 26(13):1393-1408.
19. Ulrich HD. The RAD6 pathway: control of DNA damage bypass and mutagenesis by ubiquitin and SUMO. Chembiochem: a European journal of chemical biology. 2005; 6(10):1735-1743.
20. Ulrich HD. Regulating post-translational modifications of the eukaryotic replication clamp PCNA. DNA Repair (Amst). 2009; 8(4):461-469.
21. Bergink S and Jentsch S. Principles of ubiquitin and SUMO modifications in DNA repair. Nature. 2009; 458(7237):461- 467.
22. Arakawa H, Moldovan GL, Saribasak H, Saribasak NN, Jentsch S and Buerstedde JM. A role for PCNA ubiquitination in immunoglobulin hypermutation. PLoS Biol. 2006; 4(11):e366.
23. Lin JR, Zeman MK, Chen JY, Yee MC and Cimprich KA. SHPRH and HLTF act in a damage-specific manner to coordinate different forms of postreplication repair and prevent mutagenesis. Mol Cell. 2011; 42(2):237-249.
24. Krijger PH, Lee KY, Wit N, van den Berk PC, Wu X, Roest HP, Maas A, Ding H, Hoeijmakers JH, Myung K and Jacobs H. HLTF and SHPRH are not essential for PCNA polyubiquitination, survival and somatic hypermutation: existence of an alternative E3 ligase. DNA Repair (Amst). 2011; 10(4):438-444.
25. Unk I, Hajdu I, Fatyol K, Hurwitz J, Yoon JH, Prakash L, Prakash S and Haracska L. Human HLTF functions as a ubiquitin ligase for proliferating cell nuclear antigen polyubiquitination. Proc Natl Acad Sci U S A. 2008; 105(10):3768-3773.
26. Motegi A, Liaw HJ, Lee KY, Roest HP, Maas A, Wu X, Moinova H, Markowitz SD, Ding H, Hoeijmakers JHJ and Myung K. Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Proceedings of the National Academy of Sciences. 2008; 105(34):12411-12416.
27. Unk I, Hajdu I, Fatyol K, Szakal B, Blastyak A, Bermudez V, Hurwitz J, Prakash L, Prakash S and Haracska L. Human SHPRH is a ubiquitin ligase for Mms2-Ubc13-dependent polyubiquitylation of proliferating cell nuclear antigen. Proc Natl Acad Sci U S A. 2006; 103(48):18107-18112.
28. Motegi A, Sood R, Moinova H, Markowitz SD, Liu PP and Myung K. Human SHPRH suppresses genomic instability through proliferating cell nuclear antigen polyubiquitination. J Cell Biol. 2006; 175(5):703-708.
29. Hibbert RG, Huang A, Boelens R and Sixma TK. E3 ligase Rad18 promotes monoubiquitination rather than ubiquitin chain formation by E2 enzyme Rad6. Proc Natl Acad Sci U S A. 2011; 108(14):5590-5595.
30. Hoege C, Pfander B, Moldovan GL, Pyrowolakis G and Jentsch S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature. 2002; 419(6903):135-141.
31. Sale JE. Translesion DNA synthesis and mutagenesis in eukaryotes. Cold Spring Harb Perspect Biol. 2013; 5(3):a012708.
32. Saberi A, Hochegger H, Szuts D, Lan L, Yasui A, Sale JE, Taniguchi Y, Murakawa Y, Zeng W, Yokomori K, Helleday T, Teraoka H, Arakawa H, Buerstedde JM and Takeda S. RAD18 and poly(ADP-ribose) polymerase independently suppress the access of nonhomologous end joining to double-strand breaks and facilitate homologous recombination-mediated repair. Mol Cell Biol. 2007; 27(7):2562-2571.
33. Minca EC and Kowalski D. Multiple Rad5 Activities Mediate Sister Chromatid Recombination to Bypass DNA Damage at Stalled Replication Forks. Molecular Cell. 2010; 38(5):649-661.
34. Sonoda E, Okada T, Zhao GY, Tateishi S, Araki K, Yamaizumi M, Yagi T, Verkaik NS, van Gent DC, Takata M and Takeda S. Multiple roles of Rev3, the catalytic subunit of polzeta in maintaining genome stability in vertebrates. EMBO J. 2003; 22(12):3188-3197.
35. Niedzwiedz W, Mosedale G, Johnson M, Ong CY, Pace P and Patel KJ. The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. Mol Cell. 2004; 15(4):607-620.
36. Masutani C, Kusumoto R, Yamada A, Dohmae N, Yokoi M, Yuasa M, Araki M, Iwai S, Takio K and Hanaoka F. The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. Nature. 1999; 399(6737):700- 704.
37. Motegi A, Liaw HJ, Lee KY, Roest HP, Maas A, Wu X, Moinova H, Markowitz SD, Ding H, Hoeijmakers JH and Myung K. Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Proc Natl Acad Sci U S A. 2008; 105(34):12411-12416.
38. Unk I, Hajdu I, Blastyak A and Haracska L. Role of yeast Rad5 and its human orthologs, HLTF and SHPRH in DNA damage tolerance. DNA Repair (Amst). 2010; 9(3):257- 267.
39. San Filippo J, Sung P and Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem. 2008; 77:229-257.
40. Burkovics P, Sebesta M, Balogh D, Haracska L and Krejci L. Strand invasion by HLTF as a mechanism for template switch in fork rescue. Nucleic Acids Res. 2014; 42(3):1711- 1720.
41. Petermann E, Orta ML, Issaeva N, Schultz N and Helleday T. Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51- mediated pathways for restart and repair. Mol Cell. 2010; 37(4):492-502.
42. Bryant HE, Petermann E, Schultz N, Jemth AS, Loseva O, Issaeva N, Johansson F, Fernandez S, McGlynn P and Helleday T. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 2009; 28(17):2601-2615.
43. Pathania S, Nguyen J, Hill SJ, Scully R, Adelmant GO, Marto JA, Feunteun J and Livingston DM. BRCA1 is required for postreplication repair after UV-induced DNA damage. Mol Cell. 2011; 44(2):235-251.
44. Zhao GY, Sonoda E, Barber LJ, Oka H, Murakawa Y, Yamada K, Ikura T, Wang X, Kobayashi M, Yamamoto K, Boulton SJ and Takeda S. A critical role for the ubiquitinconjugating enzyme Ubc13 in initiating homologous recombination. Mol Cell. 2007; 25(5):663-675.
45. Glaser R, Zhang HY, Yao KT, Zhu HC, Wang FX, Li GY, Wen DS and Li YP. Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci U S A. 1989; 86(23):9524-9528.
46. Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF and Chang JY. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res. 2011; 17(22):7116-7126.
47. Cole AR, Lewis LP and Walden H. The structure of the catalytic subunit FANCL of the Fanconi anemia core complex. Nat Struct Mol Biol. 2010; 17(3):294-298.
48. Hishida T, Kubota Y, Carr AM and Iwasaki H. RAD6- RAD18-RAD5-pathway-dependent tolerance to chronic low-dose ultraviolet light. Nature. 2009; 457(7229):612- 615.
49. Huen MS, Grant R, Manke I, Minn K, Yu X, Yaffe MB and Chen J. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell. 2007; 131(5):901-914.
50. Doil C, Mailand N, Bekker-Jensen S, Menard P, Larsen DH, Pepperkok R, Ellenberg J, Panier S, Durocher D, Bartek J, Lukas J and Lukas C. RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell. 2009; 136(3):435-446.
51. Mailand N, Bekker-Jensen S, Faustrup H, Melander F, Bartek J, Lukas C and Lukas J. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell. 2007; 131(5):887-900.
52. Wang B and Elledge SJ. Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci U S A. 2007; 104(52):20759-20763.
53. Khongkow P, Karunarathna U, Khongkow M, Gong C, Gomes AR, Yague E, Monteiro LJ, Kongsema M, Zona S, Man EP, Tsang JW, Coombes RC, Wu KJ, Khoo US, Medema RH, Freire R, et al. FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. Oncogene. 2013.
54. Gomes AR, Zhao F and Lam EW. Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance. Chinese journal of cancer. 2013; 32(7):365-370.
55. Zhao F and Lam EW. Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance. Frontiers of medicine. 2012; 6(4):376-380.
56. Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, Myatt SS and Lam EW. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res. 2010; 8(1):24-34.
57. Tan Y, Raychaudhuri P and Costa RH. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol. 2007; 27(3):1007-1016.
58. Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK and Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. 2012; 33(10):1843-1853.
59. Shen DW, Pouliot LM, Hall MD and Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacological reviews. 2012; 64(3):706-721.